ClinicalTrials.gg
Active, not recruitingNCT05229497Updated Mar 9, 2026

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

A Phase 1/2 interventional study of AK112 and AK117 in Advanced Malignant Tumors, sponsored by Akeso. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
154
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors

02

Conditions studied

  • Advanced Malignant Tumors
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 75 years old.
  2. Have a of at least 3 months.
  3. Have an (ECOG) performance status of 0 or 1.
  4. Phase Ib: or cytologically confirmed selected advanced solid tumor.
  5. Phase II: Subjects were patients with recurrent/ HNSCC diagnosed histologically and/or cytologically that could not be completely resected surgically and could not be treated with radical simultaneous radiotherapy, or local and or neck recurrence after radical surgery that had progressed with radiotherapy or were unsuitable for radiotherapy.

    Cohort 1 and 2 :

    Recurrent or metastatic HNSCC (non-nasopharyngeal carcinoma) that has not received systemic antitumour therapy for previous recurrent or metastatic stage and has positive expression (CPS ≥ 1); for subjects who have received previous /neoadjuvant chemotherapy for non-metastatic disease with curative intent or radical radiotherapy for locally advanced disease, if disease progression occurs after the end of the last chemotherapy session ≥ 6 months, are eligible to participate in this cohort.

    Cohort 3: Recurrent or metastatic HNSCC (non-nasopharyngeal carcinoma) that has not received systemic antitumour therapy for prior recurrent or metastatic stages; for subjects who have received prior adjuvant/neoadjuvant chemotherapy for non-metastatic disease with curative intent, or radical radiotherapy for locally advanced disease, are eligible to participate in this cohort if disease progression occurs ≥6 months after the end of the last chemotherapy treatment.

    Cohort 4: Recurrent or metastatic nasopharyngeal carcinoma that has not received systemic antitumour therapy for prior recurrent or metastatic stages; for subjects who have received prior adjuvant/neoadjuvant chemotherapy for non-metastatic disease with curative intent or radical radiotherapy for locally advanced disease, they are eligible for this cohort if disease progression occurs ≥ 6 months after the end of the last chemotherapy treatment. Note: Subjects with recurrent or residual primary foci after radiotherapy are excluded, and subjects with adenocarcinoma or sarcoma of the nasopharynx are excluded.

  6. Have at least one based on (RECIST) 1.1 assessed by investigator.
  7. Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Undergone major surgery within 30 days prior to the first dose of study treatment.
  2. Active central nervous system (CNS) .
  3. History of active disease that has required systemic treatment in the past 2 years (i.e., or drugs).
  4. Active or .
  5. Received previous immunotherapy, including , immune checkpoint agonists, immune cell therapy and other treatments targeting the mechanism of tumor immunity.
  6. History of severe bleeding tendency or coagulation disorder.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    Phase Ib#Dosage regimen 1#

    Subjects receive AK112 (20 mg/kg Q3W) + AK117 (30 mg/kg QW)

    Drug: AK112 · Drug: AK117

  • Experimental
    Phase Ib#Dosage regimen 2#

    Subjects receive AK112 (20 mg/kg Q3W) + AK117 (45 mg/kg QW)

    Drug: AK112 · Drug: AK117

  • Experimental
    Phase II#Cohort 1#

    Head and neck squamous cell carcinoma (HNSCC): AK112 (20 mg/kg Q3W)

    Drug: AK112

  • Experimental
    Phase II#Cohort 2#

    HNSCC: AK112 (20 mg/kg Q3W) + AK117 (recommended Phase 2 dose)

    Drug: AK112 · Drug: AK117

  • Experimental
    Phase II#Cohort 3#

    HNSCC: AK112 (20 mg/kg Q3W) + AK117 (recommended Phase 2 dose)+Carboplatin/Cisplatin+5-fluorouracil

    Drug: AK112 · Drug: AK117 · Drug: Carboplatin · Drug: Cisplatin · Drug: 5-Fluorouracil

  • Experimental
    Phase II#Cohort 4 regimen 1#

    Nasopharyngeal Carcinoma: AK112 (10 mg/kg d1 Q3W) + AK117(recommended Phase 2 dose)+ Cisplatin (80 mg/m2 d1 Q3W)+Gemcitabine (1000 mg/m2 d1, d8 Q3W)

    Drug: AK112 · Drug: AK117 · Drug: Cisplatin · Drug: Gemcitabine

  • Experimental
    Phase II#Cohort 4 regimen 2#

    Nasopharyngeal Carcinoma: AK112 (10 mg/kg d1 Q3W) + Cisplatin (100 mg/m2 d1 Q3W)+Gemcitabine (1000 mg/m2 d1, d8 Q3W)

    Drug: AK112 · Drug: Cisplatin · Drug: Gemcitabine

Interventions

  • DrugAK112

    IV infusion,Specified dose on specified days

  • DrugAK117

    IV infusion,Specified dose on specified days

  • IV infusion,Specified dose on specified days

  • IV infusion,Specified dose on specified days

  • IV infusion,Specified dose on specified days

  • IV infusion,Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of patients with Adverse Events (AEs)

    Characterization of incidence, severity and abnormal clinically significant laboratory findings of AEs

    Time frame: Up to approximately 2 years

  2. Number of patients experiencing dose-limiting toxicities (DLTs)

    Time frame: During the first 3 weeks

  3. Objective Response Rate (ORR)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Disease control rate (DCR)

    Time frame: Up to approximately 2 years

  2. Duration of Response (DOR)

    Time frame: Up to approximately 2 years

  3. Time to response (TTR)

    Time frame: Up to approximately 2 years

  4. Progression free survival (PFS)

    Time frame: Up to approximately 2 years

  5. Overall survival (OS)

    Time frame: Up to approximately 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2022
First posted
Feb 8, 2022
StartActual
May 4, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05229497
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Feb 8, 2022
Start date
May 4, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 9, 2026

Study contacts

Xiaozhong Chen, MD
principal investigator · Zhejiang Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion